Cirrhosis complications in children.
| Category | Complication | Treatment | When to admit | Pearls and pitfalls | |
|---|---|---|---|---|---|
| Hydrostatic pressure-related complications | Treatable by portal system decompression | Ascites | Sodium restriction |
|
|
| Spironolactone 3–6 mg/kg | |||||
| Furosemide 1 mg/kg | |||||
| Spontaneous bacterial peritonitis | 3rd generation cephalosporins |
|
| ||
| Gastroesophageal varices | Endoscopic band ligation |
|
| ||
| Octreotide 1–5 µg/kg/h | |||||
| Proton pump inhibitors BID | |||||
| 3rd generation cephalosporins | |||||
| Hepatorenal syndrome | Terlipressin + albumin |
|
| ||
| Liver transplantation | |||||
| Not treatable by portal system decompression | Hepatic encephalopathy | Lactulose 5–30 mL TID-QID |
|
| |
| Rifaximin 10–15 mg/kg/day BID | |||||
| Porto-pulmonary hypertension | Endothelin receptor antagonists (bosentan) |
|
| ||
| Phosphodiesterase-5 inhibitors (sildenafil) | |||||
| Prostacyclin analogues (epoprostenol) | |||||
| Hepatopulmonary syndrome | Liver transplantation |
|
| ||
| Not pressure-related complications | Malnutrition | MCT and essential fatty acids supplementation |
|
| |
| Vitamin A: 5,000–10,000 IU/day | |||||
| Vitamin D: 2,000–5,000 IU/day | |||||
| Vitamin E: 20–100 IU/kg | |||||
| Vitamin K: 2–10 mg/day | |||||
| Zinc: 1–2 mg/kg/day | |||||
| Hepatocellular carcinoma (HCC) | Surgical resection |
|
| ||
| Immunotherapy (PD-1/PD-L1 or CTLA-4) | |||||
| Pembrolizumab (pediatric dose to be determined) | |||||
| Liver transplantation | |||||
*: Some centers adopted the use of carvedilol as primary prophylaxis, though not much literature exists to formally adopt this practice, and its use is left to the clinician’s judgment. BID: twice daily; EVL: endoscopic variceal ligation; AKI: acute kidney injury; TID: thrice daily; QID: four times a day; NH3: ammonia; MCT: medium-chain triglycerides; BMI: body mass index; ADEK vitamins: vitamins A, D, E, K; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated protein 4.
GAC: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Validation. FÁ: Conceptualization, Writing—original draft, Writing—review & editing, Supervision, Validation. Both authors read and approved the submitted version.
GAC is a medical advisor for Mirum Pharmaceutics and Medison Pharma. GAC is also a PI in a clinical trial with Pfizer. FÁ has no conflicts of interest to declare.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.